[
  {
    "ts": null,
    "headline": "Did Positive Lung Cancer Data Just Shift Bristol Myers Squibb’s (BMY) Pipeline and Innovation Narrative?",
    "summary": "In recent days, BioNTech SE and Bristol Myers Squibb announced positive interim Phase 2 results for pumitamig plus chemotherapy in untreated extensive-stage small cell lung cancer, showing a high overall response rate and complete disease control in clinical participants. This clinical milestone was accompanied by updates at the Morgan Stanley Healthcare Conference, where Bristol Myers Squibb outlined plans to launch seven new molecular entities in the next two years and highlighted strong...",
    "url": "https://finnhub.io/api/news?id=9b88d6b123cef1b150d22ce99fbe6da6837129831ca3c914d8c2ba8ade8bca3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757505750,
      "headline": "Did Positive Lung Cancer Data Just Shift Bristol Myers Squibb’s (BMY) Pipeline and Innovation Narrative?",
      "id": 136689609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In recent days, BioNTech SE and Bristol Myers Squibb announced positive interim Phase 2 results for pumitamig plus chemotherapy in untreated extensive-stage small cell lung cancer, showing a high overall response rate and complete disease control in clinical participants. This clinical milestone was accompanied by updates at the Morgan Stanley Healthcare Conference, where Bristol Myers Squibb outlined plans to launch seven new molecular entities in the next two years and highlighted strong...",
      "url": "https://finnhub.io/api/news?id=9b88d6b123cef1b150d22ce99fbe6da6837129831ca3c914d8c2ba8ade8bca3f"
    }
  },
  {
    "ts": null,
    "headline": "Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52%",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is among the undervalued wide moat stocks to buy now. Flputnam Investment Management Co. has raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 52.4% in the first quarter, according to the recent disclosure with the Securities and Exchange Commission (SEC). After acquiring 76,321 shares, the financial services firm now owns […]",
    "url": "https://finnhub.io/api/news?id=31e8d0785148ba538948b73e6472823213e15e4a85cc736ef0fce99faf95538c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757499639,
      "headline": "Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52%",
      "id": 136689610,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is among the undervalued wide moat stocks to buy now. Flputnam Investment Management Co. has raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 52.4% in the first quarter, according to the recent disclosure with the Securities and Exchange Commission (SEC). After acquiring 76,321 shares, the financial services firm now owns […]",
      "url": "https://finnhub.io/api/news?id=31e8d0785148ba538948b73e6472823213e15e4a85cc736ef0fce99faf95538c"
    }
  }
]